Abstract
The SARS-CoV-2 Gamma variant spread rapidly across Brazil, causing substantial infection and death waves. We use individual-level patient records following hospitalisation with suspected or confirmed COVID-19 to document the extensive shocks in hospital fatality rates that followed Gamma’s spread across 14 state capitals, and in which more than half of hospitalised patients died over sustained time periods. We show that extensive fluctuations in COVID-19 in-hospital fatality rates also existed prior to Gamma’s detection, and were largely transient after Gamma’s detection, subsiding with hospital demand. Using a Bayesian fatality rate model, we find that the geographic and temporal fluctuations in Brazil’s COVID-19 in-hospital fatality rates are primarily associated with geographic inequities and shortages in healthcare capacity. We project that approximately half of Brazil’s COVID-19 deaths in hospitals could have been avoided without pre-pandemic geographic inequities and without pandemic healthcare pressure. Our results suggest that investments in healthcare resources, healthcare optimization, and pandemic preparedness are critical to minimize population wide mortality and morbidity caused by highly transmissible and deadly pathogens such as SARS-CoV-2, especially in low- and middle-income countries.
Note The following manuscript has appeared as ‘Report 46 - Factors driving extensive spatial and temporal fluctuations in COVID-19 fatality rates in Brazilian hospitals’ at https://spiral.imperial.ac.uk:8443/handle/10044/1/91875.
One sentence summary COVID-19 in-hospital fatality rates fluctuate dramatically in Brazil, and these fluctuations are primarily associated with geographic inequities and shortages in healthcare capacity.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by the Medical Research Council-Sao Paulo Research Foundation (FAPESP) CADDE partnership award (MR/S0195/1 and FAPESP18/14389-0) (https://caddecentre.org),by the EPSRC through the EPSRC Centre for Doctoral Training in Modern Statistics and Statistical Machine Learning at Imperial and Oxford. RSA from the Rede Coronaomica BR MCTI/FINEP affiliated to RedeVirus/MCTI (FINEP 01.20.0029.000462/20, CNPq 404096/2020-4), from CNPq (312688/2017-2 and 439119/2018-9), MEC/CAPES (14/2020 - 23072.211119/2020-10), FINEP (0494/2001.20.0026.00); LSB acknowledges support from Inova Fiocruz (48401485034116); DSC is funded by the Clarendon Fund, University of Oxford Department of Zoology and Merton College; NF from Wellcome Trust and Royal Society (N.R.F.: Sir Henry Dale Fellowship. 204311/Z/16/Z) and from the Bill & Melinda Gates Foundation (INV-034540); CAP was supported by FAPESP (2019/21858-0), Fundacao Faculdade de Medicina and Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior Brasil (CAPES) Finance Code 001 OTR from the Instituto de Salud Carlos III (Sara Borrell fellowship, CD19/00110); OR from the Bill & Melinda Gates Foundation (OPP1175094); ES from Bill & Melinda Gates Foundation (INV-034652); RPS from the Rede Coronaomica BR MCTI/FINEP affiliated to RedeVirus/MCTI (FINEP 01.20.0029.000462/20, CNPq 404096/2020-4),from CNPq (310627/2018-4), MEC/CAPES (14/2020 - 23072.211119/2020-10), FINEP (0494/20 01.20.0026.00), FAPEMIG (APQ-00475-20); WMS from FAPESP (2017/13981-0, 2019/24251-9) and the NIH (AI12094); CW acknowledges an MRC Doctoral Training Partnership Studentship
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study involves only openly available human data, which can be obtained from: - the SIVEP-Gripe platform (https://opendatasus.saude.gov.br/dataset/bd-srag-2021) - the Brazilian Civil Registry (https://transparencia.registrocivil.org.br/) - the Brazilian Ministry of Health (https://opendatasus.saude.gov.br/dataset/covid-19-vacinacao/resource/ef3bd0b8-b605-474b-9ae5-c97390c197a8)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵** joint senior corresponding authors.
Data Availability
All data produced are available online at: https://github.com/CADDE-CENTRE/covid19_brazil_hfr
https://opendatasus.saude.gov.br/dataset/bd-srag-2021
https://transparencia.registrocivil.org.br/
